<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10322">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02972580</url>
  </required_header>
  <id_info>
    <org_study_id>IRB16-00319</org_study_id>
    <nct_id>NCT02972580</nct_id>
  </id_info>
  <brief_title>Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD</brief_title>
  <official_title>Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parent Project Muscular Dystrophy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nationwide Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Longitudinal prospective observational study. This is a 24-month study with the possibility
      of extending the data time points. Initially baseline, then 12 and 24 months follow up
      studies will be completed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three cohorts are enrolled in this study. The target population is the cohort of genetically
      confirmed DMD/BMD female carriers (Cohort A). This cohort will consist of 150 DMD/BMD
      mothers who are somatic carriers of a mutation in the DMD gene. The data collected for this
      cohort will be compared to two control groups; Control Group B is a cohort of 50 DMD/BMD
      mothers who are NOT somatic carriers and Control Group C is a cohort of 50 age-matched
      healthy controls. The inclusion of a Control Group B allows for a comparison to a group of
      mothers that share the emotional and cognitive burden of caring for an affected male without
      having the physical or cognitive risks of being a female carrier. The Control Group C offers
      robust data from an age-matched healthy cohort for purposes of comparison.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Function</measure>
    <time_frame>2 years</time_frame>
    <description>Cardiac function as defined by cardiac MRI studies and treadmill SVO2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skeletal Muscle Strength</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory biomarkers</measure>
    <time_frame>2 years</time_frame>
    <description>Laboratory biomarkers of disease and stress burden: CK enzyme level, hair cortisol levels, pro-inflammatory markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WAISI</measure>
    <time_frame>2 years</time_frame>
    <description>WAISI online survey for caregiver stress</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <condition>Becker Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Cohort A:</arm_group_label>
    <description>DMD/BMD Female Carriers (n=150)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <description>DMD/BMD Female non-carriers controls= (n=50)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <description>Healthy Age-Matched Controls (n=50)</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic characterization</intervention_name>
    <description>Longitudinal prospective observational study</description>
    <arm_group_label>Cohort A:</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The blood sample for genetic testing will be delivered to the Molecular Genetics lab at
      Nationwide Children's Hospital, where genomic DNA will be isolated from peripheral white
      blood cells. DNA will be banked frozen while a portion of the sample will be delivered to
      the Emory Molecular Genetics Laboratories for testing of the DMD gene.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cohort A: DMD/BMD Female Carriers (n=150) Cohort B: DMD/BMD Female non-carriers controls=
        (n=50) Cohort C: Healthy Age-Matched Controls (n=50)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Cohort A requires a genetically confirmed mutation in the DMD gene with an affected
             son

          -  Cohort B includes DMD/BMD mothers with NO somatic mutation in the DMD gene

          -  Cohort C age-matched healthy controls with a normal CK level

          -  Able to complete testing in English

          -  Able to consent

        Exclusion Criteria:

          -  Subjects with a contraindication to cardiac or skeletal muscle MRI

          -  Subjects on heart failure medication at time of enrollment

          -  Subjects on steroid treatment

          -  Presence of an inherited neurologic disease or comorbidity that may affect their
             ability to complete this study

          -  Has a medical condition or extenuating circumstance that, in the opinion of the
             investigator, might compromise the subject's ability to comply with the protocol
             required testing or procedures or compromise the subject's wellbeing, safety, or
             clinical interpretability
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dan Jenkins, Bachelors</last_name>
    <phone>614-355-2602</phone>
    <email>Daniel.Jenkins@nationwidechildrens.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nationwide Children's Hosptial</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Jenkins</last_name>
      <phone>614-355-5602</phone>
      <email>Daniel.Jenkins@nationwidechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Katie Church, MSW</last_name>
      <phone>614-722-6961</phone>
      <email>kathleen.church@nationwidechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Samiah Al-Zaidy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>May Ling Mah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jerry Mendell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kan Hor, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda Cripe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jamie Jackson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lindsay Alfano</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 21, 2016</lastchanged_date>
  <firstreceived_date>July 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nationwide Children's Hospital</investigator_affiliation>
    <investigator_full_name>Samiah Al-Zaidy</investigator_full_name>
    <investigator_title>Physician/Assistant Professor- Department of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
